Patients receiving radiotherapy to treat high-risk prostate cancer benefit from androgen deprivation therapy, and length of treatment may be dependent on radiation deliver, according to a recent study.
Menu
Browsing: Clinical Breakthroughs
The drug darolutamid, administered with standard androgen-deprivation therapy and docetaxel chemotherapy, increased survival in patients with metastatic hormone-sensitive prostate cancer.
Associate vice president of research Richard D’Aquila, MD, shares his perspective on the news of a possible third person cured of HIV, and the progress of HIV research in the future.
A new combination of antiviral drugs did not improve clinical outcomes in hospitalized patients with severe influenza, warranting further investigation into new therapeutic strategies, according to a recent clinical trial.
Treating breast tumors alongside distant metastases did not improve outcomes in women with stage IV breast cancer, according to a new study.
A novel combination treatment approach extended survival in mice with pancreatic cancer, demonstrating a potential second-line therapy for patients.
Sequencing known cardiac arrythmia genes in more than 20,000 people without an indication for genetic testing identified pathogenic variants in nearly one percent of individuals.
A novel gene therapy promoted transfusion independence in more than 90 percent of adult and pediatric patients with transfusion-dependent beta-thalassemia, according to a recent clinical trial published in The New England Journal of Medicine.
A new Northwestern Medicine study suggests that some patients with the most common type of heart failure may benefit from a novel, minimally invasive cardiac implant device called an atrial shunt.
Neural stem cells engineered by Northwestern Medicine investigators used in combination with the HER2 inhibitor drug tucatinib improved survival in mice with HER2 positive breast cancer brain metastases.